Protagen NavigAid SSc

Dec 13, 2016

Progtagen has launched the NavigAid systemic sclerosis (SSc) disease stratification assay for use in drug development.

NavigAid SSc achieves patient stratification by measuring serum biomarkers and has been specifically developed to address heterogeneity in patients with the disease. The assay enables differential diagnosis, risk stratification, and prediction of organ involvement.

Breaking News

NanoString, A*Star, Next Level Genomics to Launch Spatial Biology Laboratory in Singapore
FDA Approves Entrogen's RAS Mutation Detection Kit as CDx for Vectibix
Cancer Predisposition Variants Increase Secondary Cancer Mortality Risk in Pediatric Survivors
BostonGene, Johns Hopkins University Partner for Multiple Cancer Clinical Research Projects
KromaTid, Noble Life Sciences Ink Distribution, OEM Agreement

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.